Xiaowei Xu
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 116
- Cutaneous Melanoma Detection and Management 47
- Cancer Immunotherapy and Biomarkers 24
- CAR-T cell therapy research 21
- Cancer Cells and Metastasis 17
- Immunology 60
- Immunotherapy and Immune Responses 34
- Immune Cell Function and Interaction 13
- Immune cells in cancer 13
- Co-authors
- Meenhard Herlyn (23 shared papers)David E. Elder (30 shared papers)Shujing Liu (26 shared papers)Giorgos Constantine Karakousis (35 shared papers)Lynn Mara Schuchter (24 shared papers)Thiennga K. Nguyen (3 shared papers)Suresh Kumar (11 shared papers)Ravi K. Amaravadi (20 shared papers)
- Journals
- Clinical Cancer Research (15 papers)Nature Communications (12 papers)Cancer Research (9 papers)Journal of Cutaneous Pathology (8 papers)Cell Reports (8 papers)
- Partner nations
- United StatesChinaAustralia
In The Last Decade
Xiaowei Xu
262 papers receiving 28.0k citations
Xiaowei Xu's Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 13.4k
- Immunology 8.3k
- Cancer Research 4.0k
- Molecular Biology 12.2k
- Cell Biology 1.7k
Countries citing papers authored by Xiaowei Xu
This map shows the geographic impact of Xiaowei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaowei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaowei Xu more than expected).
Fields of papers citing papers by Xiaowei Xu
This network shows the impact of papers produced by Xiaowei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaowei Xu. The network helps show where Xiaowei Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaowei Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 270 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response Hit paper breakdown → | 2018 | 2378 |
| 2 | Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Hit paper breakdown → | 2015 | 2052 |
| 3 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Hit paper breakdown → | 2010 | 1518 |
| 4 | T-cell invigoration to tumour burden ratio associated with anti-PD-1 response Hit paper breakdown → | 2017 | 1361 |
| 5 | TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion Hit paper breakdown → | 2019 | 1191 |
| 6 | A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas Hit paper breakdown → | 2005 | 1082 |
| 7 | Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K Hit paper breakdown → | 2010 | 1064 |
| 8 | Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms Hit paper breakdown → | 2020 | 785 |
| 9 | Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients Hit paper breakdown → | 2016 | 646 |
| 10 | Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification Hit paper breakdown → | 2011 | 560 |
| 11 | A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma Hit paper breakdown → | 2019 | 550 |
| 12 | Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors Hit paper breakdown → | 2017 | 545 |
| 13 | Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy Hit paper breakdown → | 2017 | 537 |
| 14 | 2014 | 396 | |
| 15 | Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility Hit paper breakdown → | 2018 | 349 |
| 16 | 2016 | 333 | |
| 17 | Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) Hit paper breakdown → | 2021 | 310 |
| 18 | 2006 | 291 | |
| 19 | 2012 | 272 | |
| 20 | 2016 | 228 |
About Xiaowei Xu
Xiaowei Xu is a scholar working on Oncology, Immunology, Cancer Research, Molecular Biology and Cell Biology, having authored 270 papers that have together received 28.5k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (47 papers), Immunotherapy and Immune Responses (34 papers), Melanoma and MAPK Pathways (34 papers), Cancer Immunotherapy and Biomarkers (24 papers), CAR-T cell therapy research (21 papers), Cancer Cells and Metastasis (17 papers), Immune Cell Function and Interaction (13 papers) and Immune cells in cancer (13 papers). The work is most often cited by research in Oncology (13.4k citations), Immunology (8.3k citations), Cancer Research (4.0k citations), Molecular Biology (12.2k citations) and Cell Biology (1.7k citations). Xiaowei Xu has collaborated with scholars based in United States, China and Australia. Frequent co-authors include Meenhard Herlyn, David E. Elder, Shujing Liu, Giorgos Constantine Karakousis, Lynn Mara Schuchter, Thiennga K. Nguyen, Suresh Kumar, Ravi K. Amaravadi, Phyllis A. Gimotty and Géza Ács. Their work appears in journals such as Clinical Cancer Research, Nature Communications, Cancer Research, Journal of Cutaneous Pathology and Cell Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.